VEGFR3: The overall HR for survival in patients expressing high tumor cell VEGFR3 was 1.48 (95% CI: 0.77–2.86) across 5 studies using a random effects model and including 747 patients (Fig 2C, Table 3). This evidence concerns the gene FLT4 and neoplasm.